Viropro(OTC) VPRO

Current Price$0.00

Market Cap$127.00K

Since IPO (2011)-100%

5 Year-92%

1 Year+9,900%

1 Month+9,900%

Viropro last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-05-13

Viropro stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9,900%	USD 0.00	2026-04-22
1 month	+9,900%	USD 0.00	2026-02-20
3 month	+316.67%	USD 0.00	2025-12-22
Year to date	+316.67%	USD 0.00	2025-12-22
1 year	+9,900%	USD 0.00	2025-04-09
3 year	+9,900%	USD 0.00	2023-05-10
5 year	-91.67%	USD 0.00	2021-05-12
Since inception	-99.81%	USD 0.05	2011-07-05

Viropro Financials at a Glance

Market Cap

$127.00K

Revenue (TTM)

$1.01M

Net Income (TTM)

-$2.24M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-78.96 (Low)

Dividend

$0.00

Beta (Volatility)

-78.96 (Low)

Price

$0.00

Volume

300

Open

$0.00

Price

$0.00

Volume

300

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

-78.96 (Low)

Price

$0.00

Volume

300

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

VPRO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viropro

Viropro Inc. is a biotechnology company specializing in the development and manufacturing of biotherapeutic proteins. As a contract research and manufacturing organization, Viropro focuses on producing biogeneric therapeutic proteins for various medical conditions, including cancer and diabetes.

Products and Services

Development of biotherapeutic proteins for clinical trials
Manufacturing of biosimilars and monoclonal antibodies
Contractual research services for biotech and biopharmaceutical companies

Growth Outlook

Partnership with Oncobiologics for monoclonal antibody commercialization
Expansion into industrial-scale manufacturing of biogeneric proteins
Focus on treating high-demand illnesses like cancer and diabetes

Financial Highlights

Recent quarterly revenue of $385,156, showing growth potential
Trailing twelve months (TTM) gross profit margin of 100%
Current ratio of 0.26 indicates liquidity challenges

Viropro Inc. operates in a competitive biotechnology sector, providing essential services to clients in need of biotherapeutic solutions. The company's focus on developing and manufacturing proteins positions it well for future growth, especially with its strategic partnerships and innovative technologies. Despite facing liquidity challenges, the recent revenue figures and strong gross profit margin suggest a potential for recovery and expansion. Investors may find Viropro's commitment to addressing critical health issues appealing as the company navigates its path in the biotechnology landscape.

AI Generated • Jun 29, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

San Jose, CA 95131, US

VPRO Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-174.49%

Net Income Margin

-176.88%

Return on Equity

-185.71%

Return on Capital

-61.06%

Return on Assets

-47.79%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$127.00K

Shares Outstanding

1.27B

Volume

300

Avg. Volume

4.839

Financials (TTM)

Gross Profit

$1.01M

Operating Income

-$2.01M

EBITDA

-$1.96M

Operating Cash Flow

-$287.96K

Capital Expenditure

$0.00

Free Cash Flow

-$287.96K

Cash & ST Invst.

$119.25K

Total Debt

$12.05M

Viropro Performance Analysis

Viropro sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2010-12-31	-1.2%
Q1	2011-03-31	33.6%
Q2	2011-06-30	-4.4%
Q3	2011-09-30	73.5%

Viropro sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2010-12-31	100.0%
Q1	2011-03-31	N/A
Q2	2011-06-30	-1900.0%
Q3	2011-09-30	40.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2011YOY CHG

Revenue

$385.16K

+119.0%

Gross Profit

$385.16K

+119.0%

Gross Margin

100.00%

N/A

Market Cap

$127.00K

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$1.04M

-538.7%

EBITDA

-$777.57K

-405.0%

Quarterly Fundamentals

Name

Q3 2011YOY CHG

Total Cash

$119.25K

+500.3%

Total Debt

$12.05M

+6610.6%

Accounts Receivable

$82.70K

-40.3%

Inventory

$50.63K

N/A

Long Term Debt

$11.91M

N/A

Short Term Debt

$141.06K

-21.4%

Return on Assets

-47.79%

N/A

Return on Invested Capital

-68.42%

N/A

Free Cash Flow

$365.09K

+955.9%

Operating Cash Flow

$341.51K

+887.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MCETMultiCell Technologies, Inc.

MCETMultiCell Technologies, Inc.$0.00+0.00%

YECOEV Biologics, Inc.

YECOEV Biologics, Inc.$0.00+0.00%

PRCNFPure Global Cannabis Inc.

PRCNFPure Global Cannabis Inc.$0.00+0.00%

TSOITherapeutic Solutions International, Inc.

TSOITherapeutic Solutions International, Inc.$0.00+0.00%

SQZBSQZ Biotechnologies Company

SQZBSQZ Biotechnologies Company$0.02+0.00%

EMMAEmmaus Life Sciences, Inc.

EMMAEmmaus Life Sciences, Inc.$0.01+0.00%

BITRFBiotron Limited

BITRFBiotron Limited$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

STAKStak

STAKStak$9.27+6.02%

Questions About VPRO

What is the current price of Viropro?

Viropro is trading at $0.00 per share.

What is the 52-week range for Viropro?

Over the past 52 weeks, Viropro has traded between $0.00 and $0.00.

How much debt does Viropro have?

Viropro total debt is unavailable.

How much cash does Viropro have on hand?

Viropro does not have cash on hand data available.

What is Viropro’s dividend yield?

Viropro does not currently have a dividend yield.

Viropro(OTC) VPRO

Viropro Financials at a Glance

VPRO News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Viropro

VPRO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Viropro Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VPRO

What is the current price of Viropro?

What is the 52-week range for Viropro?

How much debt does Viropro have?

How much cash does Viropro have on hand?

What is Viropro’s dividend yield?

Premium Investing Services